Recurrent Serious Infections in a Human with Primary Progressive Multiple Sclerosis on Ocrelizumab
A 61-year-old woman with clinically stable PPMS experienced severe infections requiring hospitalization while receiving ocrelizumab. Despite the absence of inflammatory activity, ocrelizumab was discontinued after multiple infections, and she did not experience relapse in the following months without treatment.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This case highlights the potential complications of long-term ocrelizumab treatment in PPMS, emphasizing the need for careful patient monitoring and individualized treatment decisions based on infection history and health status.
What this does not prove
This case report does not establish broader conclusions about the safety or effectiveness of ocrelizumab in PPMS patients with similar risks, as it focuses on a single individual.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Case report
- Participants / samples
- 1 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- PPMS
- Publication date
- 2026-09-20
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceOcrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report. ↗DOI: 10.7759/cureus.116594
Supporting passages (8)
limitationsTitle: Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report.
study phaseA single case cannot establish age-based or universal discontinuation thresholds; instead, it supports individualized shared decision-making regarding treatment continuation, interval extension, temporary interruption, or discontinuation.
study designThis case underscores the need to reassess long-term therapy according to recent disease activity, cumulative treatment exposure, immunologic monitoring, infection history, functional status, comorbidities, care context, and patient goals.
subjectsA 61-year-old woman with PPMS and no recent clinical or radiographic evidence of inflammatory disease activity while receiving ocrelizumab every six months was hospitalized three times over approximately five months.
sample sizeA single case cannot establish age-based or universal discontinuation thresholds; instead, it supports individualized shared decision-making regarding treatment continuation, interval extension, temporary interruption, or discontinuation.
relevant ms typesTitle: Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report.
findingsAfter the first two infectious admissions, the next scheduled infusion was withheld; following the osteomyelitis admission, neurology recommended discontinuation, and the patient remained off disease-modifying therapy without documented relapse at the last follow-up.
publication datePublication date: 2026-09-20
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.